Immatics N.V. (IMTX) Social Stream

Immatics N.V. (IMTX): $11.31

0.09 (+0.80%)

POWR Rating

Component Grades








Add IMTX to Watchlist
Sign Up

Industry: Biotech




#65 of 359

in industry

Featured Post From StockTwits About IMTX

$IMTX Anyone with stocks in $CVAC $MRNA $ABCL or $LIFE is welcome to look at $IMTX.

Immatics publishes results for the second quarter of 2021 as well as an update on business development Patient recruitment for the ACTengine® studies continues to go according to plan; By the end of July, a total of 27 patients with various types of cancer had been treated with the product candidates IMA201, IMA202 or IMA203 Progress in the development of bispecific TCR molecules: IMA401 program on the way to clinical trial approval, publication of preclinical proof-of-concept data for the second TCER® program IMA402 On June 30, 2021, Immatics had cash and cash equivalents of 192.8 million euros (229.1 million US dollars1), which is expected to cover operating costs through 2023
Holdiwatmunter, published August 11, 2021

What Else are IMTX Traders Talking About?

Other tickers frequently mentioned alongside IMTX are CVAC, MRNA, ABCL and LIFE.

Loading social stream, please wait...

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!